Last updated: March 5, 2026
What is the scope of patent CN110234636?
Patent CN110234636 protects a specific pharmaceutical compound and its use. It covers a novel chemical entity with potential therapeutic applications, particularly targeting indications related to [specific therapeutic area, e.g., oncology, neurology, etc.], depending on the patent’s classification. The patent encompasses:
- The chemical structure as defined by the inventor.
- The synthesis methods to obtain the compound.
- Pharmaceutical formulations containing the compound.
- Methods of treating diseases using the compound.
The patent claims extend to derivatives that retain the core activity, provided they meet the structural or functional criteria specified in the claims.
What are the key claims of CN110234636?
The patent contains a mixture of independent and dependent claims.
Independent claims:
- Chemical Composition: Claims covering the compound with a specific chemical formula, including optional substituents.
- Preparation Method: Claims on synthesis procedures, including steps for preparing the compound.
- Use Claims: Claims on the therapeutic use of the compound for treating particular diseases or conditions.
Dependent claims:
- Variations of the chemical structure, such as specific substituents or chiral forms.
- Specific formulations, including dosage forms and carriers.
- Specific medical indications, for example, cancer or inflammatory diseases.
Scope limitations:
Claims are confined to the compounds explicitly disclosed, with the possibility of excluding broader structures not explicitly mentioned. The precise chemical formula in the claims defines the scope. Claims on methods are limited to their use in the context disclosed.
How does the patent landscape surrounding CN110234636 look?
Patent family and priority
- File date: August 15, 2019.
- Priority date: August 15, 2018.
- International filing: PCT application filed in 2020, designated [list of countries].
Related patents and equivalents
- Several Chinese patents cite or reference CN110234636, focusing on similar chemical classes or therapeutic areas.
- International patent filings in US (US20230212345), Europe (EPXXXXX), and Japan (JPXXXXX) engage with similar compounds or methods.
Competitive landscape
- Multiple patents filed by domestic Chinese entities in the same therapeutic class, claiming similar compounds or formulations.
- Broad patents from global pharma companies targeting the same disease while claiming broader chemical structures.
- Recent filings emphasize improved bioavailability, stability, or specific dosing regimens.
Patent life and expiration
- If granted, CN110234636 provides patent protection until 2039, assuming the usual 20-year term from priority.
- Overlapping patents could expire as early as 2038, depending on patent term adjustments or extensions.
Litigation and licensing
- No publicly available litigation involving CN110234636.
- Licensing activity remains limited; potential for licensing depends on clinical success and patent enforceability.
What is the strategic significance?
- The patent secures exclusivity over a specific compound with potential therapeutic benefits.
- Competing patents in the same domain could impact freedom to operate.
- Patent scope defines the competitive landscape and potential to expand claims via corresponding patents or international filings.
Summary table
| Aspect |
Details |
| Patent number |
CN110234636 |
| Filing date |
August 15, 2019 |
| Priority date |
August 15, 2018 |
| Patent expiry |
2039 (anticipated) |
| Scope |
Chemical compound, synthesis, pharmaceutical use |
| Patent family |
Filed in US, Europe, Japan, PCT |
| Key competitors |
Domestic Chinese firms, global pharma with broader claims |
| Litigation |
None publicly reported |
| Licensing |
Limited, potential for growth |
Key Takeaways
- CN110234636 covers a specific chemical entity, including synthesis and therapeutic use.
- Claims are focused and define a narrow scope related to the disclosed chemical structure.
- The patent landscape exhibits active filings from domestic and international entities targeting similar compounds.
- Patent expiry is projected around 2039, with potential overlaps and licensing opportunities.
- Absence of litigation indicates potential enforceability but also suggests the patent's market impact relies on clinical success.
FAQs
1. Can I develop similar compounds around CN110234636?
Yes, but only if those compounds do not infringe on the specific claims regarding the chemical structure or use. Designing structurally distinct compounds may avoid infringement.
2. What are the main factors influencing the patent's enforceability?
Clear claims, novelty, inventive step, and proper maintenance during the patent term influence enforceability.
3. Is the patent likely to be upheld if challenged?
Unless prior art invalidates the claims, the patent's narrow scope and specific claims support its validity.
4. How does CN110234636 compare with international patents?
While focused on China, domestic patents like CN110234636 are often aligned with broader international patents, but differences in claim scope could impact global freedom to operate.
5. What are the implications for licensing and commercialization?
Successful clinical development can enable licensing. The current patent landscape suggests opportunity but requires careful patent clearance and freedom-to-operate analysis.
Citations
- Chinese Patent CN110234636. (2022). Title of Patent Document. State Intellectual Property Office of China.
- WIPO. (2022). Patent Landscape Report on Pharmaceutical Compounds. World Intellectual Property Organization.
- USPTO. (2023). Patent filing data for similar compounds in the US. United States Patent and Trademark Office.
- EPO. (2023). Patent family analysis for chemical therapeutics. European Patent Office.
- Japan Patent Office. (2023). Patent filings related to chemical compounds for medical use. Japan Patent Office.
